Jean-pierre Després

Learn More
Dariush Mozaffarian, MD, DrPH, FAHA; Emelia J. Benjamin, MD, ScM, FAHA; Alan S. Go, MD; Donna K. Arnett, PhD, MSPH, FAHA; Michael J. Blaha, MD, MPH; Mary Cushman, MD, MSc, FAHA; Sandeep R. Das, MD, MPH; Sarah de Ferranti, MD, MPH; Jean-Pierre Després, PhD, FAHA; Heather J. Fullerton, MD, MAS; Virginia J. Howard, PhD, FAHA; Mark D. Huffman, MD, MPH, FAHA;(More)
BACKGROUND Rimonabant, a selective cannabinoid-1 receptor (CB1) blocker, has been shown to reduce body weight and improve cardiovascular risk factors in obese patients. The Rimonabant in Obesity-Lipids (RIO-Lipids) study examined the effects of rimonabant on metabolic risk factors, including adiponectin levels, in high-risk patients who are overweight or(More)
OBJECTIVE Consumption of sugar-sweetened beverages (SSBs), which include soft drinks, fruit drinks, iced tea, and energy and vitamin water drinks has risen across the globe. Regular consumption of SSBs has been associated with weight gain and risk of overweight and obesity, but the role of SSBs in the development of related chronic metabolic diseases, such(More)
Excess intra-abdominal adipose tissue accumulation, often termed visceral obesity, is part of a phenotype including dysfunctional subcutaneous adipose tissue expansion and ectopic triglyceride storage closely related to clustering cardiometabolic risk factors. Hypertriglyceridemia; increased free fatty acid availability; adipose tissue release of(More)
CONTEXT Abdominal obesity is associated with metabolic abnormalities and increased risk of atherosclerotic cardiovascular disease. However, no obesity management strategy has demonstrated the ability to slow progression of coronary disease. OBJECTIVE To determine whether weight loss and metabolic effects of the selective cannabinoid type 1 receptor(More)
Marc-Andre Cornier, MD, Chair; Jean-Pierre Després, PhD, FAHA; Nichola Davis, MD, MS; Daurice A. Grossniklaus, RN, MEd, PhD; Samuel Klein, MD, FAHA; Benoit Lamarche, PhD, FAHA; Francisco Lopez-Jimenez, MD, MSc; Goutham Rao, MD; Marie-Pierre St-Onge, PhD; Amytis Towfighi, MD; Paul Poirier, MD, PhD, FAHA; on behalf of the American Heart Association Obesity(More)
There is currently substantial confusion between the conceptual definition of the metabolic syndrome and the clinical screening parameters and cut-off values proposed by various organizations (NCEP-ATP III, IDF, WHO, etc) to identify individuals with the metabolic syndrome. Although it is clear that in vivo insulin resistance is a key abnormality associated(More)
Obesity has recently emerged as a major global health problem. According to World Health Organization estimates, 1.6 billion adults worldwide were overweight (body mass index [BMI] 25 kg/m) and at least 400 million were obese (BMI 30 kg/m) in 2005, numbers that are expected to reach 2.3 billion and 700 million, respectively, by 2015. In the United States,(More)
The prevalence of obesity has increased worldwide and is a source of concern since the negative consequences of obesity start as early as in childhood. The most commonly used anthropometric tool to assess relative weight and classify obesity is the body mass index (BMI); BMI alone shows a U- or a J-shaped association with clinical outcomes and mortality.(More)